With new hemodialysis reduced mortality

Treatment of emodialitici (ANSAmed) – Barcelona, April 16 – with a new therapy called HighVolumeHDF leads to a reduction in mortality of 30%. This is what emerged the catalan study Eshol, supported by the Catalan society of Nephrology and published in the journal of the American Society of Nephrology. Other studies had highlighted the positive aspects of HDF online in the control of anemia, reduction of beta2-microglobulin and reduce inflammatory effects. All rights reserved